Navigation Links
Neurosciences Institute Discovers Drug Extends Stroke Treatment Time to 24 Hours, Repairs Brain Tissue
Date:9/1/2008

Could Be Life-Changing for Stroke, Traumatic Brain Injury, Alzheimer's

Patients

MORGANTOWN, W.Va., Sept. 1 /PRNewswire-USNewswire/ -- Scientists at the Blanchette Rockefeller Neurosciences Institute (BRNI) have discovered that Bryostatin -- and a related class of drugs discovered at BRNI -- administered 24 hours after stroke can rescue and repair brain tissue. These findings are markedly advanced compared to current stroke treatments that must be administered within three hours and are unable to repair damaged brain tissue.

In an article to be published in the September 3 issue of the Proceedings of the National Academy of Sciences (PNAS), BRNI Scientific Director and Toyota Chair Daniel Alkon, M.D. and Professor Miao-Kun Sun, PhD describe how this Alzheimer's candidate drug repairs the brain and improves memory.

"Today's stroke patient has precious minutes to receive care without suffering irreversible damage or death. One of the greatest challenges in modern medical practice is finding an effective treatment that extends that treatment time and repairs damage," said BRNI Scientific Director Daniel Alkon, M.D. "Bryostatin could be an answer."

Bryostatin could be life changing for millions of Americans who suffer neurological conditions -- from Alzheimer's disease to stroke. Each year in the United States, there are more than 780,000 strokes. It is the third leading cause of death in the country and the most common cause of long-term disability in developed countries. Nearly three-quarters of all strokes occur in people over the age of 65 and the risk of having a stroke more than doubles each decade after the age of 55.

"We're facing an aging Babyboomer population, an influx of 55-plus Americans, and treatment that is less time-restrictive and able to repair the brain if a stroke destroys tissue is urgently needed," said Alkon.

How Bryostatin Works

Stroke symptoms typically develop rapidly -- within seconds to minutes -- and as oxygen becomes depleted in the brain tissue, cells die. This means that hundreds of thousands of neurons -- each linked to thousands of connections -- die. In animal testing, Bryostatin completely rescues these dying neurons, stimulates the growth of new connections and restores memory capacity. Additionally, the drug can be administered up to 24 hours following a stroke, increasing the number of patients it could potentially save.

This drug, suggests Alkon, offers potential to prevent and/or reverse brain degeneration not just in stroke victims, but also Alzheimer's disease and traumatic brain injury.

Previous studies had also shown Bryostatin's ability to accelerate the generation of new connections in the brain when paired with learning exercises. According to Alkon, this could eventually lead to new treatment therapies for children with compromised memory activity. BRNI is in discussion with the Food and Drug Administration (FDA) to begin clinical trials of the drug.

About BRNI

BRNI is the world's only non-profit institute dedicated to the study of both human memory and diseases of memory. Its primary mission is to accelerate the transfer of neurological discoveries from the lab to the doctor's office where it can benefit patients who suffer from neurological and psychiatric diseases.

BRNI is operated in alliance with West Virginia University in Morgantown as well as in collaboration with other academic institutions such as Johns Hopkins University. West Virginia Senator Jay Rockefeller founded the Institute in memory of his mother, Blanchette Hooker Rockefeller, who died of Alzheimer's disease.


'/>"/>
SOURCE Blanchette Rockefeller Neurosciences Institute
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Intellect Neurosciences, Inc. and Medical Research Council Technology (U.K.) Reach Important Milestone in Generating an Alzheimers Therapeutic Antibody
2. Knopp Neurosciences Receives Orphan Designation for KNS-760704 for Treatment of ALS
3. Knopp Neurosciences Initiates Phase 1 Clinical Trial of KNS-760704 in ALS Development Program
4. Intellect Neurosciences, Inc. and CHDI, Inc. Enter Into Compound Testing Agreement to Evaluate OXIGON(TM) as a Potential Treatment for Huntington Disease
5. Intellect Neurosciences, Inc. to Present Data on Alzheimers Vaccine at 13th International Congress of Immunology Conference
6. Karolinska Institutet to Test Vicals Vaxfectin(R) Adjuvant With Preventive Vaccine against HIV Under Sponsorship of Swedish Institute for Infectious Disease Control
7. ALS Therapy Development Institute Partners with Clinical Centers to Establish Pathological Mechanisms of Lou Gehrigs Disease
8. Karolinska Institute to Test Vicals Vaxfectin(R) Adjuvant with Preventive Vaccine against HIV Under Sponsorship of Swedish Institute for Infectious Disease Control
9. MabVax Therapeutics Closes Two Licensing Agreements With Sloan-Kettering Institute for Cancer Research
10. New Implant Device Remotely Monitors Heart Failure Patients at Northwestern Memorials Bluhm Cardiovascular Institute
11. Seattles Swedish Cancer Institute First in U.S. to Treat Cancer Patient with Elekta VMAT
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/5/2016)... 2016  Breckenridge Pharmaceutical, Inc. announced today that ... with development and manufacturing partner Gland Pharma Limited ... of this agreement, Breckenridge will market and distribute ... the United States . The deal includes ... products cover a wide range of indications.  This ...
(Date:12/5/2016)... Oregon and PUNE, India , ... new report by Allied Market Research, titled, "Global Cancer Biomarkers ... global revenue of cancer biomarkers market is projected to reach ... a CAGR of 13.3% from 2016 to 2022. Omic technologies ... in 2015 and is expected to maintain its dominance during ...
(Date:12/5/2016)... Dec. 5, 2016  Recently Zymo Research announced ... predictor, known as Horvath,s Clock. Based on this ... analysis service to academic and biopharma scientific researchers ... sample, other than sperm. The service ... biological age versus chronological age following drug treatments ...
Breaking Medicine Technology:
(Date:12/6/2016)... ... December 06, 2016 , ... The ... formally announce its Not a Moment to Lose fundraising campaign. As the V ... dedicated to declaring victory over cancer. The campaign aims to raise $200 million ...
(Date:12/6/2016)... Pittsburgh, PA (PRWEB) , ... December 06, 2016 ... ... particle identification and characterization laboratories, is now offering HIAC particle counting and sizing ... available immediately. , Gateway Analytical instituted the new service as a response to ...
(Date:12/6/2016)... Switzerland (PRWEB) , ... December 06, 2016 , ... ... a one-stop portal for all the knowledge resources, including white papers, guides, ... certificates, and more. , To access more than 9,000 documents, webinars and ...
(Date:12/6/2016)... ... December 06, 2016 , ... ... the much-anticipated HydroFX for Water®. This first-of-its-kind water-soluble powder supplement has a ... world’s most powerful antioxidants, molecular hydrogen, HydroFX for Water transforms every day ...
(Date:12/6/2016)... ... ... Keeping Gift Season Safe, In a season stacked with gift-giving opportunities, it's ... recipients. This is the idea behind Safe Toys and Gifts Month, which sets aside ... good gifts for children. For companies that produce goods that fall into this category, ...
Breaking Medicine News(10 mins):